Italy

November 5, 2024

FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion

Pioneering a global modular network for facility design and drug production

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner to development and manufacture of biologics, vaccines, and advanced therapies. The company operates a global network with major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. For more information, go to: www.fujifilmdiosynth.com

About FUJIFILM Holdings Corporation

FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

1A Power Purchase Agreement is a long term contract between a electricity generator (the seller) and an electricity consumer (the buyer, normally a corporate or a utility) for the production and offtake of electricity. The generator constructs, operates and maintains the physical energy asset and the customer consumes and pays for the electricity delivered. PPA’s are commonly used in relation to the construction of new renewable energy assets, which are often located outside the consumers premises and delivered via the public electricity grid.

For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.

Media Contacts:

Andy Ross
FUJIFILM Europe GmbH
andy.jm.ross@fujifilm.com
+44 (0)7766 497949

Christine Jackman
FUJIFILM Holdings America Corporation
christine.jackman@fujifilm.com
914-261-4959